# V1 Empirics Check — mistralai/mistral-large-2512 (Variant C)

**Model:** mistralai/mistral-large-2512
**Variant:** C
**Date:** 2026-04-01T16:42:36.751635

---

### 1. Idea Fidelity

The paper closely adheres to the original idea manifest. It exploits the UK's staggered opt-out rollout (Wales 2015, England 2020, Scotland 2021, Northern Ireland 2023) to estimate the causal effect of deemed consent on organ donation using a difference-in-differences (DiD) design. The key outcomes—deceased donor rates, transplant rates, and consent mechanisms—are all drawn from the NHSBT data sources specified in the manifest. The paper also delivers on the promised mechanism test (family override rates) and the "organ supply paradox" (rising consent rates but stagnant transplant rates).

However, the paper deviates from the manifest in two notable ways:
- **Identification strategy**: The manifest proposed a Callaway-Sant'Anna staggered DiD, but the paper uses a simpler two-way fixed effects (TWFE) model. This is a defensible simplification given the small number of clusters (4 nations), but it should be justified more explicitly, especially since TWFE can produce biased estimates with staggered adoption.
- **Data granularity**: The manifest suggested monthly data, but the paper uses annual financial year data. This reduces statistical power and limits the ability to test for dynamic effects (e.g., anticipation or phase-in). The switch to annual data should be explained, as it weakens the original identification strategy.

### 2. Summary

This paper exploits the UK's staggered adoption of opt-out organ donation laws to test whether deemed consent increases deceased donor and transplant rates. Using a DiD design with four nations and annual data, it finds no statistically significant effect of opt-out legislation on donor or transplant rates. The null result is attributed to a key mechanism: families override deemed consent in over half of cases, rendering the legal default ineffective. The paper challenges the canonical cross-country evidence on opt-out policies and redirects attention to the bedside conversation as the binding constraint on organ supply.

### 3. Essential Points

1. **TWFE with staggered adoption is problematic**:
   The paper uses a TWFE DiD model, which can produce biased estimates when treatment effects are heterogeneous across units or time (as is likely here). With only 4 clusters, the bias from TWFE is exacerbated. The authors should either:
   - Justify why TWFE is appropriate (e.g., argue that treatment effects are homogeneous or that the bias is small relative to the null effect).
   - Switch to a more robust estimator like Callaway-Sant'Anna or Sun and Abraham, even if it reduces precision. The manifest explicitly proposed this, so the deviation needs explanation.

2. **COVID-19 confounding is not fully addressed**:
   England's opt-out law took effect in May 2020, during the pandemic. The paper acknowledges this and reports a robustness check excluding 2020/21, but the pandemic's long-run effects on ICU capacity, public health attitudes, and organ donation infrastructure may persist beyond 2020/21. The authors should:
   - Test for differential trends in donor rates between nations during the pandemic (e.g., event studies or interaction terms).
   - Discuss whether the pandemic could have masked a positive effect of opt-out (e.g., if opt-out would have increased donors but pandemic disruptions offset this).

3. **Magnitudes and standard errors are implausible for transplants**:
   The transplant effect in Column (2) of Table 1 is -15.10 transplants per million (SE = 6.19), which is economically large (25% of the pre-treatment mean) and marginally significant. However:
   - The standard error seems too small given the small sample (40 observations, 4 clusters). With only 4 clusters, cluster-robust SEs are unreliable, and the randomization inference (RI) p-value (0.25) is more appropriate. The authors should drop the robust SEs and rely solely on RI.
   - The magnitude is implausibly large relative to the deceased donor effect (-1.63). If opt-out reduced deceased donors by 1.63 pmp, how could it reduce transplants by 15.10 pmp? This suggests either a coding error (e.g., transplants are not per million) or a violation of parallel trends. The authors should reconcile this discrepancy.

### 4. Suggestions

#### Data and Identification
1. **Use monthly data if possible**:
   The manifest proposed monthly data, which would increase the sample size from 40 to ~672 observations and allow for dynamic event studies. If monthly data are available, the authors should use them to test for anticipation effects and phase-in of treatment. If not, they should explain why annual data are sufficient.

2. **Justify the switch from Callaway-Sant'Anna to TWFE**:
   The manifest explicitly proposed Callaway-Sant'Anna, which is robust to staggered adoption. The paper should either:
   - Use Callaway-Sant'Anna and compare results to TWFE.
   - Explain why TWFE is preferred (e.g., power concerns, homogeneous treatment effects).

3. **Report event studies**:
   With staggered adoption, event studies are critical for assessing parallel trends and dynamic effects. The authors should plot event study coefficients (e.g., using the `eventstudy` package in R) to show pre-trends and post-treatment effects. This would also help diagnose COVID-19 confounding.

4. **Clarify the transplant outcome**:
   The transplant effect (-15.10 pmp) is implausibly large relative to the deceased donor effect (-1.63 pmp). The authors should:
   - Confirm that transplants are per million population (not per donor).
   - Check for coding errors (e.g., are transplants aggregated across all organs?).
   - Reconcile the discrepancy with the deceased donor effect (e.g., if opt-out reduces donors, why is the transplant effect so much larger?).

#### Mechanism and Interpretation
5. **Strengthen the mechanism discussion**:
   The paper argues that family overrides explain the null effect, but the evidence is descriptive (Table 3). To strengthen this, the authors should:
   - Test whether the effect of opt-out on donor rates varies with the deemed consent authorization rate (e.g., interact opt-out with the authorization rate).
   - Compare the effect of opt-out in cases where the patient had expressed consent vs. deemed consent (if data allow).

6. **Address alternative explanations**:
   The null effect could reflect other mechanisms, such as:
   - **Crowding out**: Opt-out may reduce active registrations (e.g., if people assume they are already registered). The authors should test whether opt-out reduces opt-in registrations.
   - **Implementation failures**: If hospitals or SN-ODs did not change their practices under opt-out, the null effect could reflect poor implementation. The authors should discuss whether SN-OD training or hospital protocols changed after opt-out.

7. **Discuss external validity**:
   The UK's "soft opt-out" system (where families can override) differs from "hard opt-out" systems (e.g., Austria, where families have no veto). The authors should clarify whether their results generalize to hard opt-out systems or are specific to soft opt-out.

#### Robustness and Presentation
8. **Improve robustness checks**:
   - The "drop one nation" checks in Table 4 are useful but should be supplemented with:
     - A test for differential pre-trends (e.g., regress pre-treatment trends on treatment timing).
     - A placebo test using pre-treatment data (e.g., falsely assign treatment to earlier years and check for effects).
   - The log specification in Table 4 is helpful but should be reported alongside the level specification in the main results.

9. **Clarify the placebo test**:
   The living donor placebo (Column 3 of Table 1) is a strength, but the authors should:
   - Explain why living donors are a valid placebo (e.g., no theoretical reason to expect an effect).
   - Test whether the living donor effect is significantly different from the deceased donor effect (e.g., using a stacked regression).

10. **Revise the standardized effect sizes (Appendix Table A1)**:
    - The standardized effect sizes (SDEs) are misleading because they classify effects as "large" based on magnitude, not statistical significance. The authors should:
      - Drop the "classification" column or clarify that it refers to magnitude only.
      - Report confidence intervals for the SDEs.
    - The SDE for transplants (-1.346) is implausibly large. This reinforces the need to reconcile the transplant and donor effects.

#### Writing and Framing
11. **Tighten the abstract and introduction**:
   - The abstract should state the key result upfront: "I find no effect of opt-out on donor or transplant rates."
   - The introduction overstates the paradox ("consent rates have not risen; if anything, they have drifted downward"). Table 3 shows consent rates are stable, not declining. The authors should avoid hyperbole.

12. **Clarify the contribution relative to prior work**:
   - The paper claims to resolve the cross-country correlation puzzle, but it does not directly compare its results to Abadie and Gay (2006) or Johnson and Goldstein (2003). The authors should:
     - Replicate the cross-country analysis using their data to show how the UK results differ.
     - Discuss whether the UK's soft opt-out system explains the discrepancy with prior work.

13. **Address the "illusion" framing**:
   The title ("The Opt-Out Illusion") and conclusion imply that opt-out is purely symbolic, but the paper does not test whether opt-out has expressive or cultural effects (e.g., normalizing donation). The authors should either:
   - Soften the framing (e.g., "The Opt-Out Paradox").
   - Test for long-run cultural effects (e.g., trends in opt-in registrations or public attitudes).

### Final Assessment
This is a well-executed paper with a compelling research design and a clear null result. The key issues—identification strategy, COVID-19 confounding, and implausible transplant effects—are addressable with additional robustness checks and clarifications. The paper makes a valuable contribution by challenging the default-effect consensus in organ donation, but it should be more cautious in its framing and more rigorous in its empirical tests. With revisions, it would be suitable for a top field journal.
